A survival advantage via treatment with lenvatinib plus pembrolizumab was not seen when compared with docetaxel for advanced-stage non–small cell lung cancer whose disease progressed after previous exposure to a PD-L1 inhibitor and platinum-based chemotherapy.
Next-generation sequencing may better predict dMMR in patients with colorectal or endometrial cancer, highlighting the importance of the testing.
After 3 years, ruxolitinib provided improved control for steroid refractory or dependent chronic graft-versus-host disease when compared with best available treatment.
Adding a limited course of tremelimumab to frontline durvalumab and chemotherapy may provide patients with previously untreated metastatic non-small cell lung cancer a sustained overall survival benefit compared with chemotherapy alone.
Reducing the dose of talquetamab, a GPRC5D/CD3 bispecific antibody, may improve side effect rates while maintain high response rates in patients with relapsed or refractory multiple myeloma.
The Food and Drug Administration approved an on-body delivery system for pegfilgrastim-cbqv, a biosimilar of pegfilgrastim.
Oncology nurses may play a role in the utilization of artificial intelligence in the clinical setting.
When compared with palbociclib and fulvestrant, adding inavolisib to the regimen improved progression-free survival in some patients with PIK3CA-mutated, hormone receptor–positive, HER2-negative, locally advanced or metastatic breast cancer.
The survival benefit derived from T-DM1—particularly invasive disease-free survival and overall survival—persisted throughout 8 years of follow-up in HER2-positive early breast cancer with residual invasive disease.
Blinatumomab tended to be safe and effective in the treatment of children or young adults with B-cell acute lymphoblastic leukemia, potentially offering a treatment regimen less toxic than chemotherapy.
Oncology nurses can illuminate the potential of avasopasem to enhance pancreatic cancer outcomes and champion ongoing research.
The median overall survival among those treated with tisagenlecleucel was not reached, and the 36-month overall survival rate was 82%.
The major molecular response rate for asciminib at week 156 continued to be higher than with bosutinib.
In this special episode of The Vitals, we ring in the New Year 2024 by combing through 2023 FDA approvals.
Kim Noonan, DNP, ANP-BC, AOCN, FAAN, said there are things nurses can do to help manage the risk of thrombotic or cardiovascular events.
One patient speaks about her myeloproliferative neoplasm symptoms and how nurses have helped her along the way—despite issues with staffing shortages and high nursing turnover rates.
High disease burden may be associated with more bridging therapy use and contribute to worse outcomes, according to investigators.
A modified dosing schedule may make treatment with ipilimumab plus nivolumab more tolerable for patients with advanced renal cell carcinoma.
Beth Finley-Oliver, MSN, ARNP, AGNP-BC, discusses the growing number of new therapies for patients with relapsed or refractory multiple myeloma.
Olaparib improved survival outcomes in all assessed subgroups of patients with BRCA-altered metastatic castration-resistant prostate cancer.
Amy Martinez, BSN, RN, OCN, explains how her team incorporated the Timed-Up-and-Go test into their workflows on a radiology unit.
Kizzie Charles, MS, APRN, AGCNS-BC, CNOR, walks through the process of developing a successful quality improvement project in the perioperative oncology setting.
New targeted therapies offer certain patients with non–small cell lung cancer more second-line treatment options.
Delivering hazardous drugs safely is complex but essential for the welfare of our health care workers and our patients.
The 3 fundamental coping mechanisms patients should have embedded into their care plan are self-compassion, gratitude, and kindness.
Findings presented at the 2023 San Antonio Breast Cancer Symposium described some possible avenues for artificial intelligence to be useful in breast cancer care.
Most biomarkers in subgroups of patients with treatment-naive chronic lymphocytic leukemia or small lymphocytic lymphoma without del(17p) derived benefit from zanubrutinib vs bendamustine plus rituximab.
The introduction of CAR T-cell therapy for patients with relapsed/refractory multiple myeloma is considered one of the most significant advancements in the past decade.
At a median 39 months of follow-up, zanubrutinib reduced the risk of disease progression by 32% compared with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
"Differential diagnoses in patients with bicytopenia—particularly those with preserved platelets—are broad and require careful physical examination."
